ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0458

Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force

Bibi Ayesha1, Anand Kumthekar1, Ruchi Jain2, Sneha Patel3, Manish Ramesh1, Denisa Ferastraoaru4, Golda Hudes4, Merhunisa Karagic4, Sheema Zafar1, Rachel Bartash4, Natalia Vasquez-Canizares5, Elizabeth Kitsis6, Clement Tagoe7, Dawn Wahezi5, Tamar Rubinstein8 and Anna Broder3, 1Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Irvington, NY, 3Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 4Montefiore Medical Center, Bronx, 5Albert Einstein College of Medicine, Bronx, NY, 6Albert Einstein College of Medicine, New York, NY, 7Albert Einstein College of Medicine, Fresh Meadows, NY, 8Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY

Meeting: ACR Convergence 2020

Keywords: Biologicals, COVID-19, cytokines

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Infection-related Rheumatic Disease (0454–0458)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the cytokine storm syndrome (CSS).Early identification and timely, management of CSS is needed for avoiding an untoward outcome. Multi-disciplinary involvement is needed because of the complexity of the syndrome and the multi-systemic presentation. We summarize a novel approach and our experience in the formation and functioning of multidisciplinary COVID-19 CSS task force at Montefiore Medical Center in the Bronx, New York City (NYC).

Methods: As adult and pediatric rheumatologists, allergy and immunologists ( AI) are well versed with managing inflammatory disorders, after input of infectious disease (ID) and critical care team (CCM) specialists, with consensus developed a set of 4 clinical and 6 laboratory parameters to potentially help in early identification of COVID 19 patients progressing towards CSS

Every consulted patient was reviewed by a sub-specialist and discussed in daily multidisciplinary virtual conference. A consensus recommendation was made regarding steroid therapy or biologic therapy if deemed appropriate. All biological therapy recommended by the CSS task force required a final approval from designated physician from ID or CCM.

Results: Between April 4,2020 and May 7,2020, the CSS consult service evaluated a total of 288 patients. Patients who received biologic therapy were younger with a median age of 53 years (IQR= 32-63 years) versus 62.5 years (52-70 years) in the no-biologic group (p=0.008). A higher proportion of patients receiving biologics were in the critical care setting {26 (84%) vs 151 (59%), p= 0.006}, were on mechanical ventilation {26 (84%) vs 146 (57%), p=0.003} and on vasopressors {22 (71%) vs 111 (43%), p=0.003}. Patients who received biologics were more likely to have a longer median duration of steroid therapy 12.5 days (IQR= 6-15 days) vs 8 days (IQR= 5-12 days) (p=0.01).

Conclusion: To our knowledge, this is the first multi-disciplinary team model collaborative effort to provide consensus recommendations for COVID-19 patients at risk of developing CSS, which is a unique experience at our institution where multiple sub-specialities came together to create a consult service to help early identify and treat  patients with COVID-19 CSS, at a time of unparalleled COVID-19 surge with limited resources in NYC.

Table 1: Clinical and Laboratory Parameters based on consensus recommendations of the COVID-19 CSS Task Force.

Table 2: Characteristics of COVID-19 patients evaluated by the CSS Task Force

Table 3: Treatment Profile of Patients Evaluat-ed by the COVID-19 CSS Task Force


Disclosure: B. Ayesha, None; A. Kumthekar, None; R. Jain, None; S. Patel, None; M. Ramesh, None; D. Ferastraoaru, None; G. Hudes, None; M. Karagic, None; S. Zafar, None; R. Bartash, None; N. Vasquez-Canizares, None; E. Kitsis, None; C. Tagoe, None; D. Wahezi, None; T. Rubinstein, None; A. Broder, None.

To cite this abstract in AMA style:

Ayesha B, Kumthekar A, Jain R, Patel S, Ramesh M, Ferastraoaru D, Hudes G, Karagic M, Zafar S, Bartash R, Vasquez-Canizares N, Kitsis E, Tagoe C, Wahezi D, Rubinstein T, Broder A. Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/rapid-implementation-of-a-multidisciplinary-covid-19-cytokine-storm-syndrome-task-force/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rapid-implementation-of-a-multidisciplinary-covid-19-cytokine-storm-syndrome-task-force/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology